Who is sponsoring NCT00620074?

NCT00620074 is sponsored by Pfizer.

What condition does NCT00620074 study?

NCT00620074 studies Aspergillosis.

What drugs are being tested in NCT00620074?

Interventions: voriconazole, anidulafungin.

What is the status of NCT00620074?

NCT00620074 is currently TERMINATED.

Last reviewed 2010-01-21 · How we verify

Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment

NCT00620074 Phase 4 TERMINATED Results posted

This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.

Details

Lead sponsor	Pfizer
Phase	Phase 4
Status	TERMINATED
Enrolment	6
Start date	2008-08
Completion	2009-02

Conditions

Aspergillosis

Interventions

voriconazole
anidulafungin

Primary outcomes

Summary of Global Response at End of Treatment (EOT) — End of Treatment (Day 42)
Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

Countries

United States